Increased endodiastolic volume and decreased ejection fraction in GJB4-deficient zebrafish. by Ryuji Okamoto (614374)

Baseline characteristics of study participants. by Zixia Qian (21474969)

“…For each age group, the mumps IgG seroprevalence rates were 74.40%, 89.02%, 85.58%, 68.60%, 69.28%, 78.42%, and 80.63% for those <8 months, 8 months-2 years, 3–5 years, 6–17 years, 18–39 years, 40–59 years, and>=60 years, respectively. In terms of the percentage decreases in anti-mumps antibody titers, in the population receiving the 1-dose vaccine, there was a mean decrease of 2.06% per year. …”

The numerical data used in this study. by Zixia Qian (21474969)

“…For each age group, the mumps IgG seroprevalence rates were 74.40%, 89.02%, 85.58%, 68.60%, 69.28%, 78.42%, and 80.63% for those <8 months, 8 months-2 years, 3–5 years, 6–17 years, 18–39 years, 40–59 years, and>=60 years, respectively. In terms of the percentage decreases in anti-mumps antibody titers, in the population receiving the 1-dose vaccine, there was a mean decrease of 2.06% per year. …”

ngLVA degradation kinetics. by Nicole A. Grieshaber (11175417)

“…<p>Cos-7 cell infected with L2-euoprom-ngLVA, treated with 34 μg/ml chloramphenicol (CAM) or vehicle only (1:1000 EtOH in RPMI) at 35 hpi (arrow). …”

STAT6-driven immunity decreases <i>N</i>. <i>brasiliensis</i> reproductive output and survival within host. by Annabel A. Ferguson (17616286)

The effect of R55H, D149E, and G59R on the structure of RAD52. by Abdulaziz B. Hamid (13804692)

Geographical distribution of anemia among children 6–59 months. by Samnang Um (14990562)

Nrf2 activation decreases PMN ROS production in response to zymosan. by Doumet Georges Helou (7255823)

Incidence rates of colorectal cancer by race in the U.S. active-duty military and U.S. general population, ages 20–59, 1990–2013. by Julie A. Bytnar (11383752)

Incidence rates of selected digestive cancers in the U.S. active-duty military and U.S. general population, ages 20–59, 1990–2013. by Julie A. Bytnar (11383752)

Transcriptomic and metabolomic analyses of liver of <i>Fmo5</i>^<i>-/-</i> and WT mice. by Ian R. Phillips (5074121)

“…<p>(A) Volcano plot representation of differentially expressed genes (log₂-fold change) of <i>Fmo5</i>^<i>-/-</i> vs WT mice. Red dots are genes whose expression is significantly increased or decreased in <i>Fmo5</i>^<i>-/-</i> mice with a -log₁₀ <i>q</i> above 1.301 (<i>q</i> <0.05) (grey line). …”

Effects of vidarabine, V2E, V3E and V5E on AC activity in the heart of WT and AC5KO mice. by Kenji Suita (750993)

“…<p>(A) Vidarabine (Vida), V2E, V3E and V5E similarly and significantly decreased ISO (50 µmol/L)-stimulated AC activity in the WT heart in a dose-dependent manner. …”

Effect of water content on CO₂ absorption compared to 30 wt% aqueous MEA. by Hossam K. Abdrabou (16436541)

Subjects:

TSLPR deficient mice show decreased AHR upon HDM exposure. by Latifa Koussih (326043)

Pharmacological characterization of WT BMP9 and A347E variant <i>in vitro</i> and <i>in vivo.</i> by Tobias G. Schips (21799838)

The <i>TgCRT</i>-deficient parasites displayed a swollen vacuole and a disrupted endolysosomal system. by L. Brock Thornton (6808385)

“…During replication, the VAC in WT and Δ<i>crtCRT</i> parasites became fragmented. …”

2wT scale-up flow chart. by Phiona Marongwe (6818120)

GXM decreases the trans-endothelial electrical resistance (TEER) and transmigration of <i>C</i>. <i>neoformans</i> through HBECs in a blood brain barrier (BBB) model. by Hiu Ham Lee (15374677)

Incidence rates of colorectal and stomach cancers by age in the U.S. active-duty military and U.S. general population, ages 20–59, 1990–2013. by Julie A. Bytnar (11383752)

Sample characteristics (N = 59). by Mel Major (15285799)

“…Longitudinal changes in outcomes and potential associations between MIP/MEP, predictor variables, and secondary outcomes were investigated through linear mixed model analysis.</p><p>Results</p><p>A total of 59 participants (male: 64%, median age [IQR]: 62 [53–66]) were included in this study with a median (IQR) ICU and hospital length of stay of 11 (8–21) and 35 (21–52) days respectively. …”